BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16684580)

  • 1. Prioritisation by physicians in the Netherlands--the growth hormone example in drug reimbursement decisions.
    de Bont A; Zandwijken G; Stolk E; Niessen L
    Health Policy; 2007 Mar; 80(3):369-77. PubMed ID: 16684580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional reimbursement within the Dutch drug policy.
    Niezen M; de Bont A; Stolk E; Eyck A; Niessen L; Stoevelaar H
    Health Policy; 2007 Nov; 84(1):39-50. PubMed ID: 17207886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the selection of patients for anti-retroviral treatment in Uganda fair? A qualitative study.
    Sofaer N; Kapiriri L; Atuyambe LM; Otolok-Tanga E; Norheim OF
    Health Policy; 2009 Jun; 91(1):33-42. PubMed ID: 19070932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National HIV treatment guidelines in Tanzania and Ethiopia: are they legitimate rationing tools?
    Johansson KA; Jerene D; Norheim OF
    J Med Ethics; 2008 Jun; 34(6):478-83. PubMed ID: 18511624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fairness and accountability for reasonableness. Do the views of priority setting decision makers differ across health systems and levels of decision making?
    Kapiriri L; Norheim OF; Martin DK
    Soc Sci Med; 2009 Feb; 68(4):766-73. PubMed ID: 19070414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden.
    Jansson S
    Health Econ Policy Law; 2007 Apr; 2(Pt 2):153-71. PubMed ID: 18634660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethically acceptable prioritisation of childless couples and treatment rationing: "accountability for reasonableness".
    Lindström H; Waldau S
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):176-86. PubMed ID: 18417271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priority setting and cardiac surgery: a qualitative case study.
    Walton NA; Martin DK; Peter EH; Pringle DM; Singer PA
    Health Policy; 2007 Mar; 80(3):444-58. PubMed ID: 16757057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of health technology assessment in shaping the benefits package in The Netherlands.
    Stolk EA; de Bont A; van Halteren AR; Bijlmer RJ; Poley MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):85-94. PubMed ID: 19371181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug evaluation by the French National Health Authority for reimbursement decisions].
    Bouvenot G
    Bull Acad Natl Med; 2005 Nov; 189(8):1683-90; discussion 1690-1. PubMed ID: 16737094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing norms: Canadian rural family physicians' perceptions of clinical practice guidelines and shared decision-making.
    Boivin A; Légaré F; Gagnon MP
    J Health Serv Res Policy; 2008 Apr; 13(2):79-84. PubMed ID: 18416912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding.
    Sinclair S; Hagen NA; Chambers C; Manns B; Simon A; Browman GP
    Health Policy; 2008 May; 86(2-3):381-90. PubMed ID: 18243395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationing cancer treatment: a qualitative study of perceptions of legitimate limit-setting.
    Feiring E; Wang H
    BMC Health Serv Res; 2018 May; 18(1):342. PubMed ID: 29743065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local prioritisation work in health care--assessment of an implementation process.
    Waldau S
    Health Policy; 2007 May; 81(2-3):133-45. PubMed ID: 16824642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Justice and procedure: how does "accountability for reasonableness" result in fair limit-setting decisions?
    Rid A
    J Med Ethics; 2009 Jan; 35(1):12-6. PubMed ID: 19103936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decentralized health care priority-setting in Tanzania: evaluating against the accountability for reasonableness framework.
    Maluka S; Kamuzora P; San Sebastiån M; Byskov J; Olsen ØE; Shayo E; Ndawi B; Hurtig AK
    Soc Sci Med; 2010 Aug; 71(4):751-9. PubMed ID: 20554365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.